ArticleMedical science monitor : international medical journal of experimental and clinical research2024
Shiga Toxin-Producing E. coli and Hemolytic Uremic Syndrome: A Study of the 2022 Outbreak in Turkey.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Shiga toxin-producing Escherichia coli (STEC) causes serious bacterial illnesses from consuming undercooked meat and foods contaminated with feces. This study aimed to describe the characteristics of an STEC outbreak associated with hemolytic uremic syndrome (HUS) that emerged in Turkey and affected 21 adults. MATERIAL AND METHODS The medical records of 21 adult patients who were admitted to Ankara Bilkent City Hospital Internal Medicine Intensive Care Department with the diagnosis of HUS between July and September 2022 were retrospectively evaluated through the system. RESULTS While a positive correlation was detected between the length of hospital stay and N-terminus pro-B-type natriuretic peptide (NT-proBNP), lactate dehydrogenase (LDH), and troponin during hospitalization, a negative correlation was detected with glomerular filtration rate (GFR). Patients requiring plasmapheresis had higher creatinine, amylase, and LDH values at the time of admission. In patients given eculizumab, high NT-proBNP and creatinine levels and low GFR levels at the time of admission were found to be statistically significant. The use of antibiotics before admission did not change the length of hospital stay. CONCLUSIONS A statistically significant difference was detected between LDH, GFR, troponin, NT-proBNP parameters, and length of hospital stay. Creatine and LDH values of patients requiring eculizumab and plasmapheresis at the time of admission were found to be statistically high. It should be kept in mind that eculizumab and plasmapheresis treatment can be required for patients with elevated creatine and LDH at the time of admission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.